Prognostic value of pretreatment cardiovascular biomarkers in head and neck squamous cell carcinoma

Oliveira, Karine Gadioli; Thebit, Marcela Marçal; Andrade, Tadeu Uggere de; Campos, Fabiana V.; Podestá, José Roberto Vasconcelos de; Zeidler, Sandra Ventorin von; Bissoli, Nazaré Souza; Gouvêa, Sônia Alves

doi:10.1111/odi.13691

Cited by 4 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous study has shown that pretreatment hs-cTnT had no influence over the prognosis in patients with head and neck squamous cell carcinoma [ 10 ]. These finding suggest that troponin may have different prognostic value in different cancer patients.…”

Section: Discussionmentioning

confidence: 99%

“…There is a growing interest in the relationship between cancer therapy and cardiovascular complications such as pericardial and myocardial disease, left ventricular dysfunction, and ultimately heart failure [ 7 ]. However, there are only a few studies dedicated to investigating the association between cardiac biomarkers with all-cause death in cancer patients prior to the tumor resection surgery [ 8 – 10 ]. Such studies had small sample sizes, etiological heterogeneity and different conclusions [ 11 ], therefore, no consensus can be reached.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The association of preoperative high-sensitivity cardiac troponin i and long-term outcomes in colorectal cancer patients received tumor resection surgery

Zhang

Huang²,

Hu³

et al. 2023

Cardio-Oncology

View full text Add to dashboard Cite

Background This study aimed to evaluate the association between preoperative hs-cTnI and long-term mortality and major adverse cardiovascular events (MACE) in colorectal cancer patients. Methods This single-center retrospective cohort study included 1105 consecutive colorectal cancer patients who received tumor resection surgery between January 2018 and June 2020. Inclusion criteria were an age ≥ 18 years and had been tested for hs-cTnI on admission within 7 days prior to tumor resection surgery. Exclusion criteria were emergent surgery, failure to received tumor resection surgery, hospital death, there was clinical evidence of unstable coronary artery disease or pulmonary embolism occurred before operation according to medical record. The primary endpoint was all-cause death. Secondary endpoint was major adverse cardiovascular events (MACE). Results A total of 1105 patients were enrolled: 1032 with normal hs-cTnI and 73 with elevated hs-cTnI. The mean follow-up was 24.4 ± 10.8 months, 176 patients died and 39 patients met MACE. In the elevated troponin group, 50%, 32.1% and 17.9% died from cancer, cardiovascular and other causes, while those in the normal troponin group were 75.7%, 2% and 22.3%, there was statistical difference between 2 groups (P < 0.001). Patients with elevated preoperative hs-cTnI had significantly higher mortality (P < 0.001) and more MACE (P < 0.001) compared with those with normal hs-cTnI. A propensity-matching analysis were performed, resulting in 151 patients with normal hs-cTnI and 60 patients with elevated hs-cTnI. The matched population had the similar results for all-cause death (P = 0.009) and MACE (P = 0.001). The results were consistent after further excluding 147 patients who had received chemoradiotherapy prior to surgery in subgroup analysis. The results of multivariate Cox regression analysis shown that hs-cTnI was one of the best predictors for all-cause death (hazard ratio [HR] 2.278; 95% confidence interval [CI] 1.19–4.361) and MACE (HR, 3.523; 95%CI, 1.477–8.403) in total populations, similar results were found in subgroup analysis. Conclusions Colorectal cancer patients without myocardial ischemia manifestation but with elevated hs-cTnI prior to tumor resection surgery were at increased risk for long-term all-cause death and MACE, irrespective of whether they have received chemoradiotherapy prior to surgery.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The association of preoperative high-sensitivity cardiac troponin i and long-term outcomes in colorectal cancer patients received tumor resection surgery

Zhang

Huang²,

Hu³

et al. 2023

Cardio-Oncology

View full text Add to dashboard Cite

show abstract

“…Based on the inflammatory link between tumors, their microenvironment, and the systemic response [7], different inflammatory markers were analyzed for their prognostic potential in various cancer entities including head and neck malignancies. Studies have shown the correlation of survival outcome in patients with head and neck carcinoma with several different inflammation-associated markers such as the neutrophil-to-lymphocyte ratio (NLR) [8,9], platelet-to-lymphocyte ratio (PLR) [10], and C-reactive protein (CRP) [11]. In our previous study, we assessed the prognostic significance of certain inflammatory biomarkers in ACC and observed an association of outcome with NLR values [12].…”

Section: Introductionmentioning

confidence: 99%

The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

Brkic

Stoiber

Friedl

et al. 2021

JPM

View full text Add to dashboard Cite

Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (n = 28) compared to the high pretreatment FLR group (n = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; p = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; p = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results.

show abstract

Cardiac dysfunction in solid tumours: scoping review

Brady,

Brown,

Barrett

et al. 2023

BMJ Support Palliat Care

View full text Add to dashboard Cite

Cardio-oncology is a dynamic field. Research has suggested that cancer itself can damage the heart, independent of cancer treatment-related cardiac dysfunction (CTRCD). The aim of this study was to establish the nature of cardiovascular abnormalities reported in cancer, excluding CTRCD. Scoping review search included cardiovascular abnormalities in adults with solid tumour malignancies, and excluded CTRCD and thrombotic events. Three databases (CINAHL, Embase, Medline) were searched, supplemented by a handsearch. All screening and data extraction was done by two researchers with consensus reached for any conflicts. Given the heterogeneous nature of the studies identified, data synthesis was narrative. The search identified 42 366 studies. Following deduplication and title/abstract screening, 195 studies were assessed for full-text eligibility. Forty-four studies are included in the final analysis. There are 19 prospective observational studies, 13 retrospective studies, 9 case reports and 3 cross-sectional studies. Types of abnormality identified include cardiomyopathy (16, including Takotsubo (9)), autonomic nervous system (ANS) dysfunction (10), biomarker disturbances (9), reduced myocardial strain (6) and others (3). Due to variable study design, the prevalence was not determined. Cardiovascular abnormalities were associated with morbidity (chest pain, dyspnoea, fatigue) and shortened prognosis. In conclusion: (1) There is evidence for cardiovascular dysfunction in patients with solid tumour malignancies, distinct from CTRCD. People with solid tumours have higher rates of cardiac disease, even when newly diagnosed and treatment naïve. (2) Abnormalities manifest mainly as cardiomyopathies, ANS dysfunction and raised biomarker levels and are associated with significant symptoms. (3) Treatment plans need to take account of these risks, and widen criteria for screening.

show abstract

Prognostic value of pretreatment cardiovascular biomarkers in head and neck squamous cell carcinoma

Cited by 4 publications

References 38 publications

The association of preoperative high-sensitivity cardiac troponin i and long-term outcomes in colorectal cancer patients received tumor resection surgery

The association of preoperative high-sensitivity cardiac troponin i and long-term outcomes in colorectal cancer patients received tumor resection surgery

The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

Cardiac dysfunction in solid tumours: scoping review

Contact Info

Product

Resources

About